focus -WSS

focus

author：knowledge 2025-09-28 23:49:45 - browse：38

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday released a new accounting of artificial intelligence tools cleared for use in health care, adding scores of new products designed to reshape care in several areas of medicine.

The update included 171 new products that use artificial intelligence and machine learning, including 155 authorized since August of 2022. The agency’s data indicate that, after a lull during the Covid-19 pandemic, the number of authorized devices in 2023 is expected to increase by more than 30% over the prior year.

The list of AI devices was first published after a STAT investigation reported that the FDA had failed to keep the public informed on its regulation of AI devices, or crucial details on the tests undertaken to prove their safety and effectiveness. The summary documents that describe new AI devices often fail to break out the demographics of the patients they were tested on, or where the testing took place, which makes it difficult for clinicians and patients to understand their potential biases and weaknesses.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： NIH director takes cautious approach to Biden drug pricing priority

WSS

Independent physicians launch a new lobbying group

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Eli Lilly, Pfizer, and others want in on the online prescription market

Physicians aren't 'burning out.' They're suffering from moral injury

Independent physicians launch a new lobbying group

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

explore

focus

focus

Novavax promises a turnaround & Lilly roils the obesity market

CDC recommends RSV monoclonal antibody for infants

Medical leaders decry Supreme Court decision on affirmative action

New brain studies show LSD's effects on the brain in full color

Peter Hotez and the public health issue of online harassment

Dewpoint Therapeutics lays off staff after losing partnerships

Trump demands the U.S. pay no more for drugs than other countries … again

eGenesis tests gene

Jerome Adams on the need for new antivirals for Covid

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Wikipedia

How digital therapeutics firms are pivoting after Pear's bankruptcy

Chris Christie meets with Zelenskyy during Ukraine trip

H.R. 3 is the wrong path to lower drug costs

Flint parents haunted by uncertainty, fears of lead poisoning

Medicare Advantage today, explained in one chart

Alnylam reports growth in sales of rare disease treatments

Wikipedia

Wikipedia

focus

knowledge